Eptifibatide

Overview

Eptifibatide is a synthetic cyclic heptapeptide antiplatelet agent developed by Millennium Pharmaceuticals (originally COR Therapeutics) and marketed as Integrilin. It received FDA approval in 1998 for the treatment of acute coronary syndrome (ACS) and for use in patients undergoing percutaneous coronary intervention (PCI), including angioplasty and stenting.

The peptide was derived from barbourin, a disintegrin protein found in the venom of the southeastern pygmy rattlesnake (Sistrurus miliarius barbouri). Disintegrins are a family of small, cysteine-rich venom proteins that inhibit integrin-mediated cell adhesion. Barbourin is unique among disintegrins in that it contains a Lys-Gly-Asp (KGD) motif rather than the more common Arg-Gly-Asp (RGD) motif, conferring high selectivity for the platelet glycoprotein IIb/IIIa (GPIIb/IIIa, also known as integrin alpha-IIb/beta-3).

Eptifibatide was designed as a KGD-containing cyclic peptide that mimics the integrin-binding domain of barbourin. By competitively blocking the GPIIb/IIIa receptor on activated platelets, it prevents fibrinogen crosslinking between adjacent platelets, the final common pathway of platelet aggregation.

Structure and Pharmacology

Molecular characteristics:

• Structure: Cyclic heptapeptide with a disulfide bridge between a mercaptopropionyl group and a cysteine residue
• Molecular weight: 831.96 Da
• Key pharmacophore: Lys-Gly-Asp (KGD) sequence within the cyclic constraint
• Administration: Intravenous bolus plus continuous infusion
• Formulation: 0.75 mg/mL and 2 mg/mL solutions for injection

GPIIb/IIIa Receptor Antagonism

GPIIb/IIIa is the most abundant integrin on the platelet surface, with approximately 50,000-80,000 copies per platelet. It undergoes a conformational change upon platelet activation (triggered by thrombin, ADP, collagen, or thromboxane A2) that exposes the ligand-binding site for fibrinogen, von Willebrand factor, and other RGD/KGD-containing adhesive proteins.

Eptifibatide's mechanism:

1. Competitive binding: The KGD motif within the cyclic peptide occupies the ligand-binding pocket of activated GPIIb/IIIa
2. Fibrinogen blockade: By occupying the binding site, eptifibatide prevents fibrinogen from bridging between adjacent activated platelets
3. Aggregation inhibition: Without fibrinogen crosslinks, platelet aggregation cannot proceed, even though platelets may be activated
4. Reversible binding: Eptifibatide binds GPIIb/IIIa with moderate affinity and rapid dissociation kinetics, allowing platelet function to recover within 4-8 hours after infusion discontinuation

This reversibility distinguishes eptifibatide from abciximab (a monoclonal antibody fragment GPIIb/IIIa inhibitor with prolonged receptor occupancy), providing a more controllable antiplatelet effect.

Selectivity

Eptifibatide demonstrates selectivity for GPIIb/IIIa (integrin alpha-IIb/beta-3) over other integrins, including alpha-V/beta-3 (vitronectin receptor) and alpha-5/beta-1 (fibronectin receptor). This selectivity is attributed to the KGD pharmacophore and the cyclic constraint, which together create a geometric and electrostatic complement specific to the GPIIb/IIIa binding pocket.

Clinical Applications

Acute Coronary Syndromes

Eptifibatide is indicated for the reduction of ischemic events in patients with non-ST-elevation ACS (unstable angina and non-ST-elevation myocardial infarction) managed medically or with PCI. It is typically administered as part of a combination antithrombotic regimen that includes aspirin and heparin (unfractionated or low-molecular-weight).

Percutaneous Coronary Intervention

In patients undergoing PCI, eptifibatide is administered as an intravenous bolus at the time of the procedure followed by a continuous infusion for 18-24 hours to prevent acute thrombotic complications at the site of coronary artery instrumentation and stent placement.

Dosing:

• ACS: 180 mcg/kg IV bolus followed by 2 mcg/kg/min continuous infusion for up to 72 hours
• PCI: 180 mcg/kg IV bolus immediately before PCI, second 180 mcg/kg bolus 10 minutes later, then 2 mcg/kg/min infusion for 18-24 hours
• Renal adjustment: Reduced infusion rate (1 mcg/kg/min) for creatinine clearance < 50 mL/min

Pharmacokinetics

Safety Profile

The primary risk associated with eptifibatide is bleeding, which is inherent to its mechanism of action:

• Bleeding: Major bleeding events (4.4-10.8% depending on definition and clinical context), including access site bleeding in PCI patients; risk is managed through careful patient selection, dose adjustment, and concurrent anticoagulant management
• Thrombocytopenia: Moderate (platelet count 50,000-100,000/mcL) in 1.2% and severe (<50,000/mcL) in 0.2% of patients; immune-mediated in some cases
• Hypotension: Reported in some patients during infusion

Eptifibatide is contraindicated in patients with active internal bleeding, history of bleeding diathesis within 30 days, history of hemorrhagic stroke, severe uncontrolled hypertension, major surgical procedure within 6 weeks, platelet count <100,000/mcL, and renal dialysis dependency.

Dosing Protocols

The following dosing information reflects FDA-approved clinical guidelines. Eptifibatide (Integrilin) is administered intravenously in hospital settings. Always consult a qualified healthcare professional.

Administration notes: Administer with aspirin and heparin as part of combination antithrombotic therapy. Contraindicated in active bleeding, recent stroke, severe hypertension, platelet count below 100,000/mcL, and renal dialysis. Platelet function recovers within 4-8 hours after infusion cessation.

Scientific Significance

Eptifibatide exemplifies the translation of venom-derived bioactive peptides into clinical therapeutics. Along with Ziconotide (cone snail venom) and Bivalirudin (leech-derived), it demonstrates how evolution has produced peptide pharmacophores with extraordinary target selectivity that can be harnessed through medicinal chemistry. The KGD motif's selectivity for GPIIb/IIIa over other RGD-binding integrins illustrates how single amino acid variations within adhesion peptide motifs can encode receptor specificity, a principle with broad implications for integrin-targeted drug design.